Larry Wittenberg is a senior partner in Goodwin’s Technology Companies & Life Sciences Group and Co-Chair of the firm’s Healthcare Technology and Services Practice. He has more than 30 years’ experience representing life science and healthcare technology companies, ranging in size from start-ups to public companies, in corporate and intellectual property transactions and general corporate matters. This work has included numerous venture capital financings, public offerings, mergers and acquisitions, strategic alliances, joint ventures, licenses and technology transfer agreements. Mr. Wittenberg also represents venture capital groups on their investments in life sciences companies and investment banks in connection with public and private financings. Mr. Wittenberg is a key contributor to Goodwin’s Founders Workbench, an online resource for start-ups, emerging companies and the entrepreneurial community. He has structured and negotiated corporate partnering transactions with numerous global pharmaceutical companies. Mr. Wittenberg co-founded the firm’s Life Sciences Practice and previously served as Co-Chair of that practice and as national Co-Chair of Goodwin's Technology Companies & Life Sciences Group.




Mr. Wittenberg’s practice focuses primarily on biotechnology, medtech and healthcare IT companies. His recent representations include:

  • Acetylon Pharmaceuticals, Inc. in its collaborative agreement with Celgene Corporation providing for $100 million in non-dilutive development financing and a buyout option of up to $1.7 billion
  • athenahealth, Inc, a provider of cloud-based electronic health records, practice management and care coordination services to doctors and hospitals, in its $293 million acquisition of Epocrates, Inc., a developer and provider of one of the most widely-used clinical information tools for healthcare professionals
  • Action Pharma, in the $110 million sale of the rights to develop and commercialize the kidney drug compound AP214 to Abbott Laboratories
  • Abide Therapeutics, Inc., in its $430 million collaboration with Merck in the metabolic disease and diabetes fields
  • Abide Therapeutics in its collaborative agreement with Celgene Corporation
  • Akashi Therapeutics in its $100 million partnership with Gruenthal Group
  • Dragonfly Therapeutics in its $33 million collaborative agreement with Celgene Corporation 
  • Patient Ping in its $31 million Series B financing
  • QPID Health in its sale to eviCore healthcare
  • Vascular Biogenics in its $15 million follow-on public offering
  • C4 Therapeutics in its launch from Dana-Farber Cancer Institute, $73 million Series A financing and strategic collaboration with Roche
  • C4 Therapeutics in its strategic collaboration with Calico Life Sciences
  • Vividion Therapeutics in its $50 million Series A financing
  • Acetylon Pharmaceuticals in its spin-out of Regenacy Pharmaceuticals and sale to Celgene Corporation
Professional Activities

Mr. Wittenberg serves on the board of directors of MassBio, an association of more than 600 biotechnology companies, universities, academic institutions and others dedicated to advancing cutting edge research.

Professional Experience

Prior to joining Goodwin, Mr. Wittenberg was a partner in the Business Practice Group at Testa, Hurwitz & Thibeault, where he co-founded and headed its Life Sciences Practice.


Mr. Wittenberg has been selected for inclusion in U.S. News-Best Lawyers.

In The News







J.D., 1979
Harvard Law School

(cum laude)

B.A., 1976
Cornell University

(magna cum laude)



Get In Touch
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.


Search Other Lawyers